At-Risk Populations

Partnership Provides HIV Prevention and Treatment Services for the Homeless

Published in AIDS Weekly, November 15th, 1999

The Tenderloin AIDS Resource Center (TARC) announced the receipt of a $35,000 grant from Bristol-Myers Squibb, makers of Zerit (also known as d4T, stavudine) and Videx (also known as ddI, didanosine).

The donation funds a program to meet the needs of homeless people in San Francisco who are at high risk of infection with HIV or who have been newly HIV infected.

Weekly, the Bristol-Myers Squibb HIV Testing and Treatment Advocacy Program provides over 30 hours of HIV antibody testing and counseling at TARC's store front operation at 187 Golden Gate Avenue and 20 hours of treatment advocacy at the Tom Waddell Health Clinic (TWHC) on Ivy Street. The...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1999-11-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry